Trading Signals: MRNA Stock Price Prediction and Forecast (Fri. Dec. 7, 2018 - Fri. Dec. 22, 2023)(Moderna, Inc)
| MRNA latest price $14.1500 (-3.41%) ($13.8184 - $14.8500) on Fri. Dec. 28, 2018. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 4.07% (three month average) | | RSI | 25 | | Latest Price | $14.1500(-3.41%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | MRNA declines -1.9% a day on average for past five trading days. | | Market Behavior | Normal for large cap. Value stock rally for small cap. | | Correlated ETFs | Broad market will support MRNA advance at 0% a week (0% probability)
IBB(44%) IPO(31%) XBI(30%) ARKG(28%) ARKK(25%) | | Factors Impacting MRNA price | MRNA will decline at least -2.035% in a week (0% probabilities).
TBT(-5%) UUP(-3%) USO(-3%) DIA(-2%) XHB(-0%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -2.035% (StdDev 4.07%) | | Hourly BBV | 0 () | | Intraday Trend | -3.9% | | | | | |
|
| 5 Day Moving Average | $14.16(-0.07%) | | 10 Day Moving Average | $15.4(-8.12%) | | 20 Day Moving Average | $0(INF%) | | To recent high | -24.7% | | To recent low | 4.7% | | Market Cap | $5.565b | | | | | | |
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.July 7, 2020 MRNA, which has developed a vaccine candidate mRNA-1273, is in its phase 2 clinical trials. The mRNA is a molecule that genetically encodes a set of instructions, based on which cells make proteins and send them to various parts of the body. |